Critical Path Still Critical, But Delayed By Drug Safety Agenda – FDA
This article was originally published in The Gray Sheet
Executive Summary
Greater investments in tracking drug safety issues could continue to slow the implementation timeline for FDA's Critical Path initiative
You may also be interested in...
Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock
A formal Critical Path priority list to be released in the coming year will include device-focused initiatives, assured FDA Deputy Commissioner for Operations Janet Woodcock
Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock
A formal Critical Path priority list to be released in the coming year will include device-focused initiatives, assured FDA Deputy Commissioner for Operations Janet Woodcock
Devices Paroled, Not Unconditionally, From Hill’s Drug Safety Hearings
House Energy & Commerce and Senate HELP staffers differ slightly in their perceptions of medical device applicability to drug safety concerns, which are the preeminent FDA issue for the 109th Congress